Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Contact lens accessory downclassification

This article was originally published in The Tan Sheet

Executive Summary

Contact lens accessory downclassification: Effective July 7, FDA reclassifies rigid gas permeable contact lens solutions, hydrophilic contact lens solutions and contact lens disinfecting units from Class III to Class II in a final rule recently published in the Federal Register. The agency states that all reviews of pending premarket approval applications for the devices are suspended and will be examined to determine those that can be converted to 510(k) submissions and those that may be exempt from 510(k) requirements. FDA asks sponsors to review their applications and advise the agency on the type of administrative action that should be taken. FDA recently announced the availability of a 510(k) guidance for the lens care products ("The Tan Sheet" June 2, p. 17)...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS087205

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel